In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corbus Pharmaceuticals Holdings Inc.

www.corbuspharma.com

Latest From Corbus Pharmaceuticals Holdings Inc.

FDA's CBD Puzzle: 'Criminals' Continue Or Prohibition Ends And Research Grows

Agency seeks comment, at May 31 public hearing and docket open through July 2, on health and safety risks, manufacturing and product quality and marketing/labeling/sales around allowing cannabis-derived ingredients non-drug products. It wants input from across sectors of stakeholders, including opponents as well as proponents of allowing cannabis-derived ingredients in any category of regulated products other than drugs.

Dietary Supplements Regulation

Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot

Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.

Financing Business Strategies

Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board

Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China. 
Deals Asia Pacific

Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma

Takeda and Molecular Templates will work to develop targeted engineered toxin bodies for multiple myeloma. Celgene decides against optioning OncoMed’s navicixizumab for ovarian cancer, while CRISPR and ViaCyte team up on type 1 diabetes.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Corbus Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Corbus Pharmaceuticals Holdings Inc.
  • Senior Management
  • Yuval Cohen, PhD, CEO
    Sean Moran, CFO
    Mark A Tepper, PhD, Pres. & CSO
    Barbara White, MD, CMO
  • Contact Info
  • Corbus Pharmaceuticals Holdings Inc.
    Phone: (617) 963-0100
    100 River Ridge Dr., Ste. 103
    Norwood, MA 02062
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register